摘要
伊立替康单药及联合方案在小细胞肺癌(SCLC)的治疗中均显示了良好的抗瘤活性,特别是与顺铂联合在SCLC的一线治疗中较足叶乙甙加顺铂方案明显延长了患者的生存期。但其独特的毒副作用腹泻发生率较高。现对伊立替康治疗小细胞肺癌的疗效及其副作用进行综述。
Irinotecan(CPT-11)is effective against small-cell lung cancer(SCLC)both in sin- gle and combined regimen.Studies of SCLC show that irinotecan and cisplatin(IP)regimen can improve patient survival compared with etoposide and cisplatin(EP)regimen as first-line treatment.However, Irinotecan-induced diarrhoea is pervasive,and can be severe and life-threatening.This article will review the response rates and side-effects of irinotecan in the treatment of SCLC.
出处
《国际肿瘤学杂志》
CAS
2006年第8期588-590,共3页
Journal of International Oncology
关键词
癌
小细胞
药物疗法
Carcinoma
small cell
Drug therapy
